Decision and Details
PresidentEarly repayment of borrowings under the limit loan agreements entered into on 16 April 2020 and 30 June 2022
To curb the increase in interest expense resulting from future interest rate rises and, by releasing the restricted deposits and financial covenants in connection with the repayment of these borrowings, enhance the liquidity and flexibility of funds available to the Company and establish a financial structure that allows it to deploy funds required for the glaucoma treatment drug “H-1337” flexibly.
The impact on the Company's consolidated results for the fiscal year ending December 2026 is immaterial.
| Item | Details |
|---|---|
| Matter Covered | Early repayment of borrowings under the limit loan agreements entered into on 16 April 2020 and 30 June 2022 |
| Decision-Making Body | President |
| Decision Date | 4 September 2026 |
| Implementation Date | 30 September 2026 (scheduled) |
| Amount | Agreement entered into on 16 April 2020: borrowing amount of ¥100 million; current balance of ¥61.904 million, Agreement entered into on 30 June 2022: borrowing amount of ¥440 million; current balance of ¥440 million |
| Quantity / scale | 2 agreements covered |
| Impact on Business Performance | The impact on the Company's consolidated results for the fiscal year ending December 2026 is immaterial. |
| Reason | To curb the increase in interest expense resulting from future interest rate rises and, by releasing the restricted deposits and financial covenants in connection with the repayment of these borrowings, enhance the liquidity and flexibility of funds available to the Company and establish a financial structure that allows it to deploy funds required for the glaucoma treatment drug “H-1337” flexibly. |
| Related previous disclosures | 16 April 2020: “Notice Regarding the Execution of a Term Loan Agreement with a Commitment Period”, 30 June 2022: “Notice Regarding the Execution of a Joint Development Agreement for a Regenerative Medicine Cell Product for Corneal Endothelial Disorders, a Capital Alliance and Borrowing of Funds” |
| Future plans | Early repayment is scheduled for 30 September 2026. The Company will notify the lender of the principal repayment amount and other details 15 business days before the early repayment date. The repayment will be funded with fixed-term deposits held at Mizuho Bank. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To curb the increase in interest expense resulting from future interest rate rises, release the restricted deposits and financial covenants in connection with the repayment, and enhance the liquidity and flexibility of funds available to the Company. The Company also aims to establish a financial structure that allows it to deploy funds required for the glaucoma treatment drug “H-1337” flexibly.